Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 337

1.

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C.

Mult Scler Relat Disord. 2019 Jan 6;29:7-14. doi: 10.1016/j.msard.2019.01.019. [Epub ahead of print]

PMID:
30654246
2.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

PMID:
30644981
3.

Screening based on risk factors for abdominal aortic aneurysm in the cardiology clinic.

Izquierdo GR, Dorrego GRM, Rodríguez LP, Segura HJV.

Int J Cardiol. 2018 Dec 27. pii: S0167-5273(18)34230-X. doi: 10.1016/j.ijcard.2018.12.059. [Epub ahead of print]

PMID:
30642648
4.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831. doi: 10.1136/jnnp-2018-319831. [Epub ahead of print]

PMID:
30636699
5.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Jan 3;28:235-243. doi: 10.1016/j.msard.2019.01.003. [Epub ahead of print]

PMID:
30623864
6.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
7.

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J.

Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20.

PMID:
30234431
8.

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.

Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M.

J Neuroinflammation. 2018 Sep 14;15(1):265. doi: 10.1186/s12974-018-1307-1.

9.

Therapeutic Drug Monitoring of Vancomycin in Pediatric Patients With Extracorporeal Membrane Oxygenation Support.

Zylbersztajn BL, Izquierdo G, Santana RC, Fajardo C, Torres JP, Cordero J, Valverde C.

J Pediatr Pharmacol Ther. 2018 Jul-Aug;23(4):305-310. doi: 10.5863/1551-6776-23.4.305.

10.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
11.

SP140 regulates the expression of immune-related genes associated with multiple sclerosis and other autoimmune diseases by NF-κB inhibition.

Karaky M, Fedetz M, Potenciano V, Andrés-León E, Codina AE, Barrionuevo C, Alcina A, Matesanz F.

Hum Mol Genet. 2018 Dec 1;27(23):4012-4023. doi: 10.1093/hmg/ddy284.

PMID:
30102396
12.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

PMID:
30083762
13.

Cross-cultural adaptation and validation of the VISA-A questionnaire for Chilean Spanish-speaking patients.

Keller A, Wagner P, Izquierdo G, Cabrolier J, Caicedo N, Wagner E, Maffulli N.

J Orthop Surg Res. 2018 Jul 13;13(1):177. doi: 10.1186/s13018-018-0882-2.

14.

[Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (II)].

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, Garcia-Merino JA, Brieva L, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Ginestal R, Martinez-Gines ML, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2018 Jul 15;67(2):50-62. Review. Spanish.

15.

[Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I)].

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, Garcia-Merino JA, Brieva L, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Ginestal R, Martinez-Gines ML, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2018 Jul 1;67(1):15-27. Review. Spanish.

16.

[Blood cultures in newborns: optimizing sample collection and performance].

Izquierdo G, García P, Aravena M, Delpiano L, Reyes A, Cofré F, Hernández M, Sandoval A, Labraña Y.

Rev Chilena Infectol. 2018 Apr;35(2):117-122. doi: 10.4067/s0716-10182018000200117. Spanish.

17.

[The challenge in colistin dosing: Updating available recommendations].

Rosales R, Rojas L, Zamora F, Izquierdo G, Benavides C, González C.

Rev Chilena Infectol. 2018 Apr;35(2):105-116. doi: 10.4067/s0716-10182018000200105. Review. Spanish.

18.

Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab.

Eichau S, López Ruiz R, Castón Osorio JJ, Ramírez E, Domínguez-Mayoral A, Izquierdo G.

Neurologia. 2018 Jun 12. pii: S0213-4853(18)30118-X. doi: 10.1016/j.nrl.2018.03.015. [Epub ahead of print] English, Spanish. No abstract available.

19.

[Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].

Eichau S, Lopez-Ruiz R, Ruiz-Pena JL, Paramo MD, Navarro-Mascarell G, Izquierdo G.

Rev Neurol. 2018 Jun 1;66(11):395-396. Spanish.

20.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35.

PLoS One. 2018 May 16;13(5):e0195891. doi: 10.1371/journal.pone.0195891. eCollection 2018.

Supplemental Content

Loading ...
Support Center